期刊文献+

应用血清RANTES诊断严重脓毒症及预后判断的价值评价 被引量:3

Diagnostic and prognostic value of serum RANTES for patients with severe sepsis
原文传递
导出
摘要 目的:检测严重脓毒症患者血清中受激活调节正常T细胞表达和分泌因子(RANTES)水平,并评价其对严重脓毒症的诊断和预后价值。方法选取严重脓毒症患者40例为严重脓毒症组(SS组),同期门诊体检者20例为对照组,收集临床及实验室参数,计算APACHEⅡ评分和 DIC 评分,采用酶联免疫吸附测定(ELISA)方法检测血清 RANTES 的水平。结果 SS组患者血清RANTES水平[(3175.91±1341.78)pg/ml]较对照组[(5374.27±927.87)pg/ml]下降(P<0.05)。相关分析显示RANTES与WBC、PLT、AST、TBIL、Cr、PT、APTT、PCT、APACHEⅡ评分和DIC评分均呈显著负相关(P<0.05),显示RANTES诊断严重脓毒症的AUCSS=0.917,95%CI 0.817-0.993(P<0.05),判断严重脓毒症死亡的AUCdeath=0.786,95%CI 0.650-0.922(P<0.05)。结论严重脓毒症患者的血清RANTES水平明显降低,并死亡率升高,对严重脓毒症的诊断和预后判断有较好的价值。 ObjectiveTo examine the levels of serum regulated upon activation normal T cell expressed and secreted (RANTES) from severe sepsis patients in an effect to evaluate the value for prognosis and diagnosis for severe sepsis.MethodsSixty patients were divided into 2 groups, severe sepsis group (SS group, 40 cases) and normal group(20 cases). Clinical data of these patients were collected, including APACHEⅡscore and DIC score. Serum levels of RANTES were measured in patients by ELISA.ResultsThe patients of SS group had lower levels of RANTES[(3 175.91±1 341.78)pg/ml] than the healthy control[(5 374.27±927.87)pg/ml](P〈0.05). There were significant negative correlations between RANTES and WBC, PLT, AST, TBIL, Cr, PT, APTT, PCT, APACHEⅡ score and DIC score (P〈0.05). The areas under the curves (AUC) of RANTES for severe sepsis was 0.917,95%CI=0.817-0.993(P〈0.05), and AUC of RANTES for death was 0.786, 95%CI=0.650-0.922(P〈0.05). Conclusion Serum levels of RANTES in patients with severe sepsis significantly decreased, which maybe benefit diagnosis and prognosis for severe sepsis.
出处 《中华临床医师杂志(电子版)》 CAS 2014年第13期47-50,共4页 Chinese Journal of Clinicians(Electronic Edition)
基金 南京军区重点科技创新项目(2013ZD22) 江西省卫计委科技计划课题(20133233)
关键词 脓毒症 趋化因子CCL5 诊断 预后 CHEMOKINE CCL5 Sepsis Diagnosis Prognosis
  • 相关文献

参考文献15

  • 1Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J] . Crit Care Med, 2013, 41(2): 580-637,.
  • 2Schorr CA, Dellinger RP. The Surviving Sepsis Campaign: past, present and future[J] . Trends Mol Med, 2014, 20(4): 192-194.
  • 3Levy MM, Dellinger RP, Townsend SR, et aI. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis[J] . Intensive Care Med, 2010,3.6(2): 222-231.
  • 4Charles PE, Gibot S. Predicting outcome in patients with sepsis: new biomarkers for old expectations[J] . Crit Care, 2014, 18(1): 108.
  • 5Cho SY, Cho1] R. Biomarkers of sepsis[J] . Infect Chemother, 2014, 46(1): 1-12.
  • 6Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy[J] . Expert Opin Bioi Ther, 2010,10(5): 725-733.
  • 7Sugitharini V, Prema A, Berla Thangam E. Inflammatory mediators of systemic inflammation in neonatal sepsis[J] . Inflamm Res, 2013, 62(12): 1025-1034,.
  • 8Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis . The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992[J] . Chest, 2009, 136(5 Suppl): e28.
  • 9Levy MM, Fink MP, Marshall JC, et al. 2001 SCCMlESrCMlACCPI ATS/SIS International Sepsis Definitions Conference[J] . Crit Care Med, 2003, 31(4): 1250-1256.
  • 10Sankar V, Webster NR. Clinical application of sepsis biomarkers[J] . I Anesth, 2013, 27(2): 269-283.

同被引文献38

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部